ABBOTT LABORATORIES vs Pfizer Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Abbott and Pfizer show two speeds of healthcare. Abbott earns steadily, a 14% net margin and a 12% return on equity, and trades near 25 times earnings. Pfizer, climbing back from the end of its pandemic boom, keeps a 12% net margin and trades cheaper, near 20 times, while paying a 6.6% dividend its 6.3% free-cash yield appears to cover. Abbott is the diversified grower at the fuller price; Pfizer is the high-yield recovery wager. One you hold for the compounding, the other for the income while it mends.
Comparison updated 2026-06-11.
| Metric | ABT | PFE |
|---|---|---|
| Price | $93.93 | $24.19 |
| Market cap | $164.1B | $138.6B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +9.6% | -4.3% |
| P/E | 26.3 | 18.5 |
| P/B | 3.11 | 1.53 |
| P/S | 3.64 | 2.19 |
| EV/EBITDA | 20.8 | 30.6 |
| Revenue growth | +6.6% | +2.1% |
| Operating margin | 12.1% | — |
| Net margin | 13.9% | 11.8% |
| Return on equity | 11.9% | 8.3% |
| Return on assets | 5.7% | 3.6% |
| Return on invested capital | 6.6% | — |
| FCF yield | 4.5% | 6.8% |
| Dividend yield | 2.6% | 7.1% |
| Debt / equity | 0.65 | 0.71 |
| Current ratio | 1.39 | 1.25 |
| Altman Z (solvency) | 7.16 | 1.85 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.